STING1 and neoplasm: [246] engineered pH‐responsive TME‐responsive nanoparticles (PMM NPs) to co‐deliver monophospholipid A (MPLA) (TLR4 agonist) and Mn3O4 (STING agonist) specifically to acidic tumor microenvironments.